Heart failure

Empagliflozin helps heart failure patients stay out of hospital

Overall, the group found that a patient’s risk of cardiovascular mortality or hospitalization for heart failure decreased as their ejection fraction increased. The treatment effect was particularly apparent when examining hospitalization rates for HF, although this impact was significantly reduced when patients had an ejection fraction greater than 65%.

“Our finding of an attenuated effect of empagliflozin on heart failure outcomes in patients with an ejection fraction of 65% and above requires further study,” the lead author wrote. Javed Butler, MD, with the Department of Medicine at the University of Mississippi School of Medicine at Jackson, and colleagues. “This subgroup represented less than 10% of the overall patient population and total number of events. Accordingly, our estimates for this subgroup are necessarily imprecise, and further studies in this subgroup are needed to clarify the true effect of empagliflozin.

Boehringer Ingelheim and Eli Lilly and Company provided support for early EMPEROR trials. Additionally, the study authors all reported working relationships with Boehringer Ingelheim.

Content related to heart failure:

Implantable atrial shunt therapy trial identifies treatable HFpEF patients

Empagliflozin Provides Consistent Benefits for Patients with HFpEF

Empagliflozin Gains FDA Approval as Treatment for Adult Patients with HFrEF

Reference:

1. Javed Butler, Milton Packer, Gerasimos Filippatos, et al. Effect of empagliflozin in patients with heart failure across the left ventricular ejection fraction spectrum. European Heart Journal, Volume 43, Issue 5, February 1, 2022, pages 416–426.